Clinical case of successful treatment of granulomatosis with polyangiitis

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic autoimmune disease characterized by the development of necrotizing inflammation in small blood vessels with damage to various organs and systems. Glucocorticosteroids (GCS) in combination with rituximab or cyclophosphamide are recommended as a pathogenetic therapy for ANCA vasculitis and help restore kidney function and reduce mortality. However, the use of these drugs is associated with certain side effects, primarily this concerns caution with respect to GCS. In this regard, there is a constant search for drugs that could ensure both the achievement of clinical remission of ANCA vasculitis (as the main goal of therapy) and a reduction in the dose, and, ideally, the cancellation of GCS. Based on the data obtained on the role of the alternative complement pathway in the pathogenesis of ANCA vasculitis, avacopan, C5a receptor inhibitor, was proposed for its treatment. In a clinical trial involving patients with ANCA-associated vasculitis, avacopan was non-inferior in achieving remission at week 26 and superior to the GCS therapy group in achieving sustained remission at week 52. All patients in the study also received cyclophosphamide or rituximab. Avacopan is recommended by KDIGO 2024 for inclusion in the induction phase of therapy to reduce the dose of GCS in patients with ANCA glomerulonephritis.

Description of the clinical case. The article presents a case of a patient with granulomatosis with polyangiitis (GPA), who was diagnosed at an advanced stage of the disease, with damage to vital organs and an extremely high risk of death. The severity of the patient's condition required mechanical ventilation with subsequent initiation of venovenous extracorporeal membrane oxygenation (ECMO), as well as renal replacement therapy. Therapy was initiated with a series of plasma exchange sessions, pulse therapy, followed by a transition to oral GCS. Taking into account the severity of glomerulonephritis and infectious complications, the decision of the council was to initiate therapy with avacopan, a drug unregistered in the Russian Federation (in combination with cyclophosphamide and rituximab).

Results. After 8 months from the start of pathogenetic therapy, the patient, who was constantly taking a minimum dose of GCS and avacopan, clinically demonstrated remission of GPA in relation to extrarenal manifestations and partial remission of glomerulonephritis.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Nadiya Frolova

City Clinical Hospital No. 52, Moscow Health Department; Russian University of Medicine

Email: nadiya.frolova@yandex.ru
ORCID iD: 0000-0002-6086-5220

Cand.Sci. (Med.), Deputy Chief Physician for Nephrology, Head of the Interdistrict Nephrology Center, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Associate Professor at the Nephrology Department, Faculty of Continuous Professional Education, Russian University of Medicine (RosUniMed)

Ресей, Moscow; Moscow

Zinaida Mutovina

City Clinical Hospital No. 52, Moscow Health Department; Central State Medical Academy

Email: zmutovina@mail.ru
ORCID iD: 0000-0001-5809-6015

Cand.Sci. (Med.), Head of the Rheumatology Department No. 1, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Associate Professor of the Department of Therapy, Cardiology and Functional Diagnostics with a course in Nephrology, Central State Medical Academy of the Administrative Dicrectorate of the President of the Russian Federation

Ресей, Moscow; Moscow

Margarita Kobzar

City Clinical Hospital No. 52, Moscow Health Department

Email: m.v.kobzar@yandex.ru
ORCID iD: 0009-0004-0236-653X

Analyst of the Project Office

Ресей, Moscow

Georgy Arbolishvili

City Clinical Hospital No. 52, Moscow Health Department; Lomonosov Moscow State University

Email: geodoc@yandex.ru
ORCID iD: 0000-0002-2252-3975

Deputy Chief Physician for Anesthesiology and Critical Care, City Clinical Hospital No. 52 of the Moscow Healthcare Department; Associate Professor at the Department of Anesthesiology and Critical Care, Faculty of Fundamental Medicine, Lomonosov Moscow State University

Ресей, Moscow; Moscow

Denis Pavlov

City Clinical Hospital No. 52, Moscow Health Department

Email: dr.pavlov@mail.ru
ORCID iD: 0009-0000-0572-8031

Head of the ICU No. 7

Ресей, Moscow

Daria Shmeleva

City Clinical Hospital No. 52, Moscow Health Department

Email: dasha068@icloud.com
ORCID iD: 0009-0001-8310-2795

Neurologist of the Rheumatology Department

Ресей, Moscow

Farid Manerov

City Clinical Hospital No. 52, Moscow Health Department

Email: faridmanerov036@gmail.com
ORCID iD: 0009-0004-6478-6652

Resuscitation Physician

Ресей, Moscow

Maryana Lysenko

City Clinical Hospital No. 52, Moscow Health Department; Pirogov Russian National Research Medical University named after N.I. Russian Ministry of Health

Хат алмасуға жауапты Автор.
Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975

Dr.Sci. (Med.), Professor, Chief Physician of the City Clinical Hospital No. 52 of the Moscow Healthcare Department; Professor at the Department of General Therapy, Pirogov Russian National Research Medical University

Ресей, Moscow; Moscow

Әдебиет тізімі

  1. Hutton H.L., Holdsworth S.R., Kitching A.R. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing. Semin. Nephrol. 2017;37(5):418–35. doi: 10.1016/j.semnephrol.2017.05.016. [PMID: 28863790].
  2. Al-Hussain T., Hussein M.H., Conca W., et al. Pathophysiology of ANCA-associated Vasculitis. Adv. Anat. Pathol. 2017;24(4):226–34. doi: 10.1097/PAP.0000000000000154. [PMID: 28537941].
  3. Watts R.A., Lane S.E., Bentham G., Scott D.G. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthrit. Rheum. 2000;43(2):414–9. doi: 10.1002/1529-0131(200002)43:2<414:AID-ANR23>3.0.CO;2-0. [PMID: 10693883].
  4. Watts R.A., Mahr A., Mohammad A.J., et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol. Dial. Transplant. 2015;30(Suppl. 1):i14–22. doi: 10.1093/ndt/gfv022. [PMID: 25805746].
  5. Jennette J.C., Falk R.J., Bacon P.A., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthrit. Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715. [PMID: 23045170].
  6. Gapud E.J., Seo P., Antiochos B. ANCA-Associated Vasculitis Pathogenesis: A Commentary. Curr. Rheum. Rep. 2017;19(4):15. doi: 10.1007/s11926-017-0641-0. [PMID: 28361331].
  7. Jennette J.C., Nachman P.H. ANCA Glomerulonephritis and Vasculitis. Clin. J. Am. Soc. Nephrol. 2017;12(10):1680–91. doi: 10.2215/CJN.02500317. [Epub 2017 Aug 25, PMID: 28842398, PMCID: PMC5628710].
  8. Jennette J.Ch., Nachman P.H. ANCA Glomerulonephritis and Vasculitis. Clin. J. Am. Soc. Nephrol. 2017;12(10):1680–91.
  9. Бекетова Т.В., Фролова Н.Ф., Столяревич Е.С. и др. Проблемы диагностики и лечения АНЦА-ассоциированных системных васкулитов: в фокусе АНЦА-негативный pauci-иммунный гломерулонефрит. Научно-практическая ревматология. 2016;54(5):543–52. [Beketova T.V., Frolova N.F., Stolyarevich E.S., et al. Problems of diagnosis and treatment of ANCA-associated systemic vasculitis: the focus is ANCA-negative pauci-immune glomerulonephritis. Sci. Pract. Rheum. 2016;54(5):543–52 (In Russ.)].
  10. Wallace Z.S., Miloslavsky E.M. Management of ANCA associated vasculitis. BMJ. 2020;368:m421. doi: 10.1136/bmj.m421. [PMID: 32188597].
  11. Hellmich B., Flossmann O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 2007;66(5):605–17. doi: 10.1136/ard.2006.062711. [Epub 2006 Dec 14, PMID: 17170053, PMCID: PMC2703775].
  12. Yates M., Watts R.A., Bajema I.M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016;75(9):1583–94. doi: 10.1136/annrheumdis-2016-209133. [PMID: 27338776].
  13. Jennette J.Ch., Nachman P.H. ANCA Glomerulonephritis and Vasculitis. Clin. J. Am. Soc. Nephrol. 2017;12(10):1680–91. doi: 10.2215/CJN.02500317.
  14. Лысенко М.А., Фролова Н.Ф., Кецкало М.В. и др. Экстракорпоральная мембранная оксигенация при жизнеугрожающем ANCA-позитивном диффузном некротизирующем геморрагическом альвеолите. Клин. Нефрология. 2018;3. Doi: https://dx.doi.org/10.18565/nephrology.2018.3.57-62. [Lysenko M.A., Frolova N.F., Ketskalo M.V., et al. ECMO in life-threatening ANCA-positive diffuse necrotizing hemorrhagic alveolitis. Clin. Nephrol. 2018;3 (In Russ.)].
  15. Kronbichler A., Lee K.H., Denicolò S., et al. Immunopathogenesis of ANCA-Associated Vasculitis. Int. J. Mol. Sci. 2020;21(19):7319. doi: 10.3390/ijms21197319. [PMID: 33023023, PMCID: PMC7584042].
  16. Xiao H., Schreiber A., Heeringa P., et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 2007;170:52–64.
  17. Hutton H.L., Holdsworth S.R., Kitching A.R. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing. Semin. Nephrol. 2017;37(5):418–35. doi: 10.1016/j.semnephrol.2017.05.016. [PMID: 28863790].
  18. Jennette J.Ch., Nachman P.H. ANCA Glomerulonephritis and Vasculitis. Clin J. Am. Soc. Nephrol. 2017;12(10):1680–91. doi: 10.2215/CJN.02500317.
  19. Huugen D., van Esch A., Xiao H., еt al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646–54.
  20. Chen M., Jayne D.R., Zhao M.H. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat. Rev. Nephrol. 2017;13:359–67.
  21. Quintana L.F., Kronbichler A., Blasco M., et al. ANCA associated vasculitis: The journey to complement-targeting therapies. Mol. Immunol. 2019;112:394–8. https://doi. org/10.1016/j.molimm.2019.06.018.
  22. Xiao H, Dairaghi D.J., Powers J.P., et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 2014;25(2):225–31. doi: 10.1681/ASN.2013020143. [Epub 2013 Oct 31, PMID: 24179165, PMCID: PMC3904560].
  23. Bekker P., Dairaghi D., Seitz L., et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016;11(10):e0164646. doi: 10.1371/journal.pone.0164646. Erratum in: PLoS One. 2019;14(1):e0210593. [PMID: 27768695, PMCID: PMC5074546].
  24. Alihosseini C., Kopelman H., Zaino M., Feldman S.R. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Ann. Pharmacother. 2023;57(12):1449–54. doi: 10.1177/10600280231161592. [Epub 2023 Mar 28, PMID: 36975183].
  25. Brilland B., Garnier A.S., Chevailler A., et al. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmun. Rev. 2020;19(1):102424. doi: 10.1016/j.autrev.2019.102424. [Epub 2019 Nov 15, PMID: 31734405].
  26. Vifor. Tavneos 10 mg hard capsules (Avacopan). Summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/tavneos-epar-product-information_en.pdf.
  27. Jayne D.R.W., Bruchfeld A.N., Harper L., et al. CLEAR Study Group. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J. Am. Soc. Nephrol. 2017;28(9):2756–67. doi: 10.1681/ASN.2016111179. [Epub 2017 Apr 11, PMID: 28400446, PMCID: PMC5576933].
  28. Merkel P.A., Niles J., Jimenez R., et al. CLASSIC Investigators. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ACR. Open Rheumatol. 2020;2(11):662–71. doi: 10.1002/acr2.11185. [Epub 2020 Oct 31, PMID: 33128347, PMCID: PMC7672305].
  29. Jayne D.R.W., Merkel P.A., Schall T.J., Bekker P. ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N. Engl. J. Med. 2021;384(7):599–609. doi: 10.1056/NEJMoa2023386. Erratum in: N. Engl. J. Med. 2024;390(4):388. [PMID: 33596356].
  30. Geetha D., Dua A., Yue H., et al. ADVOCATE Study Group. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. Ann. Rheum. Dis. 2024;83(2):223– 32. doi: 10.1136/ard-2023-224816. [PMID: 37979959, PMCID: PMC10850685].
  31. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-adults-rare-form-blood-vessel-inflammation.
  32. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1372.
  33. KDIGO ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Kidney Int. 2024;105(3S):S71–116. Доступно по ссылке: https://kdigo.org/wp-content/uploads/2024/02/ KDIGO-2024-ANCA-Vasculitis-Guideline.pdf. Accessed February 2024.
  34. Zonozi R., Aqeel F., Le D., et al. Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Kidney Int. Rep. 2024;9(6):1783–91. doi: 10.1016/j.ekir.2024.03.022.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. CT scan of the chest organs with contrast from 10/01/2023. CT picture of subtonal consolidation of the right lung, polysegmental infiltration in the left lung. Obstruction of the right upper lobe bronchus. Contents in the bronchial tree on both sides. Small bilateral pleural effusion.

Жүктеу (92KB)
Метадеректер
3. Fig. 2. CT scan of the chest organs from November 2, 2023. Regression of bilateral pulmonary infiltration with replacement by fibrosis is noted.

Жүктеу (159KB)
Метадеректер
4. Fig. 3. CT scan of the chest organs, 12/11/2023

Жүктеу (163KB)
Метадеректер
5. Fig. 4. Scheme of the conducted therapy of ANCA vasculitis

Жүктеу (154KB)
Метадеректер